Tau vaccine moving toward late-stage trials for Alzheimer’s 

AC Immune believes it has hit on a breakthrough in vaccine technology with its Alzheimer’s candidate ACI-35. The rest of the world will have to wait to evaluate the claim, as the company and partner Janssen aren’t ready to disclose the data.

The biotech announced interim results Thursday from a Phase Ib/IIa trial of the anti-tau vaccine, stating that 100% of patients responded to the vaccine and had titers “several orders of magnitude higher than pre-vaccination levels.”...